Skip to main content

Advertisement

Table 2 Characteristics of expanded cells

From: Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Patient no. CD3CD56+ CD3+CD56+ CD3+CD4+ CD3+CD8+ NKG2D+ in CD3CD56+ CD16+ in CD3CD56+ CXCR3+ in CD3CD56+ CXCR4+ in CD3CD56+ CX3CR1+ in CD3CD56+ NK activity EC50a
1 30.18 62.53 NE NE NE NE NE NE NE 2.61
2 98.41 0.93 0.40 0.24 98.91 23.01 28.33 49.79 36.79 1.31
3 81.78 16.28 17.15 0.96 96.70 20.84 48.80 21.98 28.33 1.31
4 98.75 0.91 0.55 0.13 96.28 29.47 36.67 29.78 28.37 1.61
5 72.84 26.50 25.49 1.87 99.59 68.39 44.82 20.32 39.51 0.63
6 95.67 3.93 3.12 0.30 99.36 60.70 56.62 23.31 42.07 0.62
7 86.25 13.27 3.87 0.24 95.20 50.29 29.04 31.34 26.79 1.39
8 96.60 2.27 2.25 0.07 98.54 60.46 42.90 62.89 50.40 1.24
9 84.91 14.91 10.31 2.64 98.17 72.33 41.80 37.88 62.01 0.98
10 65.94 38.83 33.61 0.23 98.67 62.79 44.04 42.40 51.40 1.88
11 98.49 1.39 0.45 0.11 99.45 69.23 49.69 69.29 44.33 1.76
12 78.52 21.40 11.43 0.30 97.88 73.50 61.05 37.54 70.20 1.99
13 97.23 2.57 2.60 0.11 99.00 32.88 57.66 49.55 54.89 0.59
14 99.45 0.44 0.28 0.09 97.82 63.59 46.12 43.73 43.15 0.39
Median (all enrolled patients) 90.96 8.60 3.12 0.24 98.54 60.70 44.82 37.88 43.15 1.31
Median (ITT population) 90.96 8.60 3.50 0.24 98.36 61.75 45.47 37.71 43.74 1.28
  1. aThe data are presented for EC50, which means the values corresponding to the E:T ratio needed to reduce the cytotoxicity by 50 % from maximum lysis